BIOARCTIC AB [CBOE] news, videos and press releases
For more news please use our advanced search feature.
BIOARCTIC AB [CBOE] - More news...
BIOARCTIC AB [CBOE] - More news...
- Eisai will request reconsideration of initial decision for lecanemab in Australia
- Study results from phase 1 studies with exidavnemab published in The Journal of Clinical Pharmacology
- Leqembi (lecanemab) authorized for early Alzheimer's disease in Great Britain
- Regarding rumors of an imminent approval of lecanemab in Great Britain: BioArctic
- Regarding rumors of an imminent approval of lecanemab in Great Britain: BioArctic
- Invitation to presentation of BioArctic's second quarter report for April - June 2024 on August 29 at 9.30 a.m. CET
- Invitation to presentation of BioArctic's second quarter report for April - June 2024 on August 29 at 9.30 a.m. CET
- Leqembi approved for the treatment of Alzheimer's disease in the United Arab Emirates
- Leqembi revenue more than doubled - totaled JPY 6.3 billion in the second quarter 2024
- Leqembi revenue more than doubled - totaled JPY 6.3 billion in the second quarter 2024
- Long-term lecanemab data show increased patient benefit with maintained safety profile
- Eisai will seek re-examination of CHMP opinion för lecanemab
- CHMP has adopted a negative opinion on lecanemab for the EU
- Long-term treatment data for lecanemab to be presented at AAIC 2024
- Leqembi approved for the treatment of Alzheimer's disease in Israel
- Leqembi approved for the treatment of Alzheimer's disease in Hong Kong
- Leqembi® (lecanemab) launched in China
- FDA accepts filing of Leqembi® (lecanemab-irmb) sBLA for IV maintenance dosing for the treatment of early Alzheimer's Disease
- Eisai projects Leqembi® revenue to total JPY 56.5 billion for fiscal year 2024 (April 2024 - March 2025)
- Eisai projects Leqembi® revenue to total JPY 56.5 billion for fiscal year 2024 (April 2024 - March 2025)
- Eisai initiates rolling Biologics License Application to US FDA for Leqembi® (lecanemab-irmb) for subcutaneous maintenance dosing
- Leqembi® revenue totaled JPY 2.83 billion in the first quarter 2024
- Leqembi® revenue totaled JPY 2.83 billion in the first quarter 2024
- BioArctic and Eisai sign research evaluation agreement regarding BAN2802
- BioArctic and Eisai sign research evaluation agreement regarding BAN2802
- The Nomination Committee's proposal for the election of Board members and Chairperson of the Board in BioArctic AB
- The Nomination Committee's proposal for the election of Board members and Chairperson of the Board in BioArctic AB
- BioArctic's focus on Sustainable Innovation qualifies company for new ESG Responsibility Index at Nasdaq Stockholm
- Submission of Leqembi® (lecanemab-irmb) sBLA for IV maintenance dosing for the treatment of early Alzheimer's disease to the U.S. FDA completed
- Lecanemab deliberations at the CHMP regarding the Marketing Authorisation Application in the EU have been rescheduled due to procedural reasons